Home Companies Catalysts Deep Dives
Adynovate rurioctocog alfa pegol APPROVED
Drug Profile
ModalityProtein
RouteIV
Therapy AreaRare Disease
Launch2015-11-13
US LOE2030-01-01
Peak Sales Est$600M
Formulations[{"id":"adynovate-iv","route":"IV","setting":"PATIENT_SELF","frequency":"Twice weekly","is_primary":
Companies
TAK (ORIGINATOR)100%
Mechanism: Factor VIII replacement
Expert: PEGylated recombinant Factor VIII with extended half-life for hemophilia A prophylaxis.
Everyday: Replaces missing clotting factor to prevent bleeding in hemophilia.
Targets: ["FVIII"]
Revenue History
PeriodRevenue ($M)
2024$290M
Programs (1)
IndicationStageKey StudyRegional Status
HemA prophAPPROVEDPROLONG-ATE[{"stage":"APPROVED","region":"US","approval_date":"2015-11-13"}]
Notes
PEGylated Factor VIII for hemophilia A. Facing competitive pressure from Hemlibra and gene therapies. Declining revenue.
Data from Supabase · Updated 2026-03-24